Shareholders’ proposal ahead of the extraordinary general meeting in Karessa Pharma on 22 October 2019
Shareholders’ representing approximately 49.8% of the shares and votes in the company propose, ahead of the extraordinary general meeting in Karessa Pharma Holding AB (publ) (”Karessa Pharma”) on 22 October 2019 that Kristina Lidén Mascher and Neal Meacham are elected as new board members.
Karessa Pharma has, at the request of shareholders representing approximately 49.8% of the shares and votes in the company convened an extraordinary general meeting at 10:00 on 22 October 2019 to consider the election of new board members.
Information regarding the board members proposed for new election
Kristina Lidén Mascher
Kristina Lidén Mascher, born 1963, is a nurse, physiotherapist and holds an MBA. She is the CEO of MAKK Consulting AB and is working as consultant in drug development projects. She is a member of the management team as clinic and QA manager on a consultancy basis of Karessa Pharma and holds a consultancy assignment as Head of Clinical Operations in Klaria Pharma Holding AB (publ).
Kristina Lidén Mascher has worked in the pharmaceutical business since 1989 and has had different responsibilities such as CEO, project manager, director clinical research and director QA at Pharmacia, Astra Zeneca, Medivir, Esperion, Electa, Remedium and Ganymed.
Kristina Lidén Mascher owns 8,720 shares in Karessa Pharma.
Neal Meacham
Neal Meacham, born 1952, is a securities adviser and holds a bachelor’s degree in sociology and anthropology. He is a project employee at Securities Services at Swedbank AB (publ) with a focus on product strategies and administrative services in the securities field.
Neal Meacham has worked with securities advising, customer trading and fund and notary services in what is today the Nordea Group. Neal Meacham also has experience from Custody and Securities Services, with a primary focus on securities services aimed at corporate and institutional clients.
Neal Meacham does not own any shares in Karessa Pharma.
For more information, please contact:
Mats Nilsson, VD Karessa Pharma Holding AB (publ)
Tel: +46-8-768 22 33
mats.nilsson@karessa.se
About Karessa Pharma Holding AB
Karessa is a Swedish pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. For more information, visit karessa.se. Certified Advisor: FNCA Sweden AB, info@fnca.se, +46-8-528 00 399.